Fosun Pharma Plans Big Increase in Foreign Drug Revenues

Shanghai Fosun Pharma has long followed an audacious business plan. In an interview with Bloomberg, Fosun's Chairman Qiyu Chen said the company expects to get 40% of its revenues from ex-China sources by 2020, up from 12% last year. To get there, Fosun has adopted an entrepreneurial structure in its innovative drug subsidiaries, Chen said, giving management an ownership share, to keep costs low and productivity high. More details.... Stock Symbols: (SHA: 600196; HK: 2196) Share this with colleagues: // //